Anti-cancer drug kicks HIV out of hiding

Danish researchers take another small step in the fight against HIV

2014-07-22

(Press-News.org) A pilot study by HIV researchers from Aarhus University and Aarhus University Hospital in Denmark has shown that an anti-cancer drug can activate hidden HIV. The researchers found that the anti-cancer drug romidepsin increased the virus production in HIV-infected cells between 2.1 and 3.9 times above normal and that the viral load in the blood increased to measurable levels in five out of six patients with HIV infection.

A pilot study The results were presented today as breaking news at the annual international AIDS conference in Melbourne, Australia. The pilot study is part of a larger study investigating the possibilities of combining activation of HIV and a vaccine to strengthen the ability of the immune system to fight HIV.

The group of researchers from Aarhus University and Aarhus University Hospital has previously shown that the drug panobinostat can activate hidden HIV in the cells but for the first time the researchers have been demonstrated that it is possible to activate hidden virus to levels readably detectable in the blood by standard methods.

Activated HIV leaves traces HIV can hide in a "state of hibernation" in the so-called CD4 cells. These cells are a part of the body's immune system, but the CD4 cells cannot fight the virus themselves; killer T-cells can. However, killer T-cells cannot tell if a CD4 cell contains "hibernating" HIV virus. That is why HIV continues to be a chronic disease. HIV infection can be kept down by medicine but there is still no cure which can eradicate HIV from the body.

The results presented by the researchers at Aarhus University Hospital and Aarhus University are interesting; when the virus is activated and moves towards the bloodstream it leaves a trace on the outside of the infected CD4 cells. In principle this means that the killer T cells can now trace and destroy the HIV-infected CD4 cells.

Immune system is not strong enough In addition to measuring the increased viral load in six HIV-infected test persons, the researchers have tested the side effects of the medicine. The test persons experienced transient fatigue and nausea, which are known side effects of romidepsin. And so, the pilot study does not cause immediate concern for special side effects in HIV-infected persons.

Moreover, the researchers have investigated if the total HIV reservoir in the body is lowered when the killer T-cells are now able to trace and destroy the HIV-infected CD4 cells. However, the researchers have not been able to demonstrate that.

The immune system's reaction to the exposed HIV-infected cells may not itself be strong enough to clear the cells from the body. But the mechanism to activate and expose the HIV virus may potentially one day be part of a combination of drugs which together can eradicate HIV infection, says senior researcher and medical doctor Ole Schmeltz Søgaard.

Still a long way to go The next step is a bigger trial where the researchers will combine romidepsin activation of hidden HIV with a vaccine (vacc-4x) to strengthen the ability of killer T-cells to fight hiv virus.

We have now shown that we can activate a hibernating virus with romidepsin and that the activated virus moves into the bloodstream in large amounts. This is a step in the right direction; but there is still a long way to go and many obstacles to overcome before we can start talking about a cure against HIV, says Ole Schmeltz Søgaard.

INFORMATION: Further information Ole Schmeltz Søgaard, MD, Senior Researcher, Aarhus University and Department of Infectious Diseases, Aarhus University Hospital, Denmark
Tel.: +45 2721 5985 ole.schmeltz.sogaard@clin.au.dk

Martin Tolstrup, Head of Research, Aarhus University and Department of Infectious Diseases, Aarhus University Hospital, Denmark
Tel.: +45 2067 9741 mtol@svf.au.dk

Thomas Rasmussen, MD, PhD-student, Aarhus University and Department of Infectious Diseases, Aarhus University Hospital, Denmark
Tel.: +45 3170 2964 thomas.rasmussen@clin.au.dk

Lars Østergaard, Professor, Administrative Consultant, Aarhus University and Department of Infectious Diseases, Aarhus University Hospital, Denmark
Tel.: +45 5151 3140 lars.ostergaard@clin.au.dk

ELSE PRESS RELEASES FROM THIS DATE:

Jeju Island is a live volcano

2014-07-22

In Jeju, a place emerging as a world-famous vacation spot with natural tourism resources, a recent study revealed a volcanic eruption occurred on the island. The Korea Institute of Geoscience and Mineral Resources (KIGAM) indicated that there are the traces that indicated that a recent volcanic eruption was evident 5,000 years ago. That is the first time to actually find out the date when lava spewed out of a volcano 5,000 years ago in the inland part of the island as well as the one the whole peninsula. The research team led by Dr. Jin-Young Lee confirmed in results ...

Unique study focuses on combined treatment approach for locally advanced pancreatic cancer

2014-07-22

LOS ANGELES (July 21, 2014) – Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer. Locally advanced pancreatic cancer has the lowest survival rate of any solid tumor, with a cumulative five-year survival rate of only 4 percent for all stages of disease. Surgery is rarely an option for patients because tumors often involve vital blood vessels. Chemotherapy and radiotherapy given ...

Vanderbilt discovery may advance colorectal cancer diagnosis and treatment

2014-07-22

A Vanderbilt University-led research team has identified protein "signatures" of genetic mutations that drive colorectal cancer, the nation's second leading cause of cancer deaths after lung cancer. The technological tour de force, described in the current issue of the journal Nature as the first integrated "proteogenomic" characterization of human cancer, "will enable new advances" in diagnosing and treating the disease, the scientists concluded. "It's a first-of-its-kind paper. I think it's a very important advance in the field," said senior author Daniel Liebler, ...

Low-income students in charter high schools less likely to engage in risky behavior

2014-07-22

A new UCLA-led study suggests that a higher quality educational environment may help improve health outcomes Low-income minority adolescents who were admitted to high-performing public charter high schools in Los Angeles were significantly less likely to engage in risky health behaviors than their peers who were not admitted to those schools, according to a new UCLA-led study. These students also scored significantly better on California state standardized math and English tests. While numerous previous studies have shown a link between health and K-12 education, ...

Strategies to preserve myelin during secondary degeneration following neurotrauma

2014-07-22

Researchers at the University of Western Australia, led by Associate Professor Melinda Fitzgerald, have discovered that preventing abnormalities in the insulating sheath surrounding nerve cells is associated with better function following neurotrauma. Following injury to the central nervous system, damage spreads away from the initial impact in a process known as secondary degeneration. Dr Fitzgerald emphasises that "In order to develop treatments for secondary degeneration, we need to understand the biochemical reactions that occur in tissue that succumbs to spreading ...

Ginkgo biloba enhances neurogenesis and improves recovery following a stroke in mice

2014-07-22

Led by Dr. Zahoor A. Shah, Dr. Shadia E. Nada and Jatin Tulsulkar (graduate student), researchers at the University of Toledo, Toledo, OH, have discovered that mice treated with Ginkgo biloba 4 hours after inducing experimental stroke and then daily for seven days had improved recovery and less brain damage than the control mice. It was also observed that Ginkgo biloba treated mice had enhanced neurogenesis, partly due to the increased protein expression of hemeoxygenase 1, an antioxidant gene that also has a role in neurogenesis. Pertinently, mice lacking the hemeoxygenase ...

Fires are a major cause of wind farm failure, according to new research

2014-07-22

*** UPDATE TO NEWS RELEASE: 'Fires are a major cause of wind farm failure, according to new research' *** Message to news release subscribers from Imperial College London Press Office: Following discussion with reporters we wish to draw attention to further information relating to the News Release issued under embargo for Thursday 17 July 2014: "Fires are a major cause of wind farm failure, according to new research". A version of this note will be appended to the online news release and news story and both will be updated accordingly. 1. The purpose of the research ...

Cleveland Clinic researchers discover neuroprotective role of immune cell

2014-07-22

July 22, 2014, Cleveland: A type of immune cell widely believed to exacerbate chronic adult brain diseases, such as Alzheimer's disease and multiple sclerosis (MS), can actually protect the brain from traumatic brain injury (TBI) and may slow the progression of neurodegenerative diseases, according to Cleveland Clinic research published today in the online journal Nature Communications. The research team, led by Bruce Trapp, PhD, Chair of the Department of Neurosciences at Cleveland Clinic's Lerner Research Institute, found that microglia can help synchronize brain firing, ...

High school lacrosse players at risk of concussions other injuries

2014-07-22

AURORA, Colo. (July 22, 2014) – With over 170,000 students now playing high school lacrosse, more and more are being exposed to injuries during practice and competition, according to a new study from the Colorado School of Public Health and the Center for Injury Research and Policy at Nationwide Children's Hospital in Columbus, Ohio. The study, published online today by The American Journal of Sports Medicine, found that high school lacrosse players experienced 1,406 injuries over the four academic years from 2008 through 2012. The overall injury rate was 20 per 10,000 ...

New planthopper species found in southern Spain

2014-07-22

Not much is known about the the genus of planthopper known as Conosimus, which now includes six species after a new one was recently discovered in the southern part of the Iberian Peninsula in the Spanish city of Jaen. A description of it appears in the open-access Journal of Insect Science (see http://www.insectscience.org/14.92/). The new species, Conosimus baenai, has been named after Manuel Baena, a Spanish hemipterologist, for his contributions to the taxonomy of Iberian Hemiptera. Conosimus baenai differs in appearance from the other species in the Conosimus genus ...

Anti-cancer drug kicks HIV out of hiding

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: